HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007 Enoxaparin could be the new standard anti-thrombotic therapy for patie
HARVEY WHITE, Auckland City Hospital, New Zealand
REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007Enoxaparin could be the new standard anti-thrombotic therapy for patients receiving fibrinolysis for ST elevation myocardial infarction. This finding is from the double-blind EXTRACT-TIMI 25 Trial which compared the low molecular weight heparin with unfractionated heparin and saw a consistent treatment superiority from enoxaparin with a reduction in repeat myocardial infarction and mortality. Sarah Maxwell spoke with the principal investigator Harvey White at the Auckland City Hospital in New Zealand.
Related Episodes
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h
